Antineoplastics
1
Reactions 1368 - 10 Sep 2011 ★ S Antineoplastics Pulmonary fibrosis (first report with ranimustine), myelodysplastic syndrome/acute myeloid leukaemia and ataxia: 5 case reports Five adult patients [age and sex not stated] developed pulmonary fibrosis (two patients), myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) (2) or ataxia during MCVAC chemotherapy for relapsed or high- risk diffuse large B-cell lymphoma [routes of administration and outcomes not stated]. These patients were retrospectively identified. All five patients were scheduled to be treated according to the MCVAC regimen (ranimustine 250 mg/m 2 on day -9 and 200 mg/m 2 on day -4, cytarabine 2.0 g/m 2 twice daily on days -8 to -5, etoposide 200 mg/m 2 twice daily on days -8 to -5 and cyclophosphamide 50 mg/kg on days -3 and -2) followed by peripheral blood stem cell transplantation (PBSCT). One patient developed cyclophosphamide-induced severe ataxia during MCVAC, and the second dose of the drug (on day -2) was omitted. Two other patients were diagnosed with pulmonary fibrosis leading to severe restrictive pulmonary impairment at 61 and 69 months post-transplant, respectively; one of these two patients had undergone whole-lung irradiation before transplantation. The remaining two patients were diagnosed with MDS/AML after 20 and 94 months from PBSCT, respectively; both had previously received salvage chemotherapy and had undergone radiation treatment. Kato J, et al. Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma. Bone Marrow Transplantation 46: 923-928, No. 7, Jul 2011. Available from: URL: http:// dx.doi.org/10.1038/bmt.2010.243 - Japan 803059753 » Editorial comment: A search of AdisBase, Medline, Embase and the WHO ADR database did not reveal any previous case reports of pulmonary fibrosis associated with ranimustine. 1 Reactions 10 Sep 2011 No. 1368 0114-9954/10/1368-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Antineoplastics
Reactions 1368 - 10 Sep 2011
★ SAntineoplastics
Pulmonary fibrosis (first report with ranimustine),myelodysplastic syndrome/acute myeloidleukaemia and ataxia: 5 case reports
Five adult patients [age and sex not stated] developedpulmonary fibrosis (two patients), myelodysplasticsyndrome (MDS)/acute myeloid leukaemia (AML) (2) orataxia during MCVAC chemotherapy for relapsed or high-risk diffuse large B-cell lymphoma [routes of administrationand outcomes not stated]. These patients wereretrospectively identified.
All five patients were scheduled to be treated accordingto the MCVAC regimen (ranimustine 250 mg/m2 on day -9and 200 mg/m2 on day -4, cytarabine 2.0 g/m2 twice dailyon days -8 to -5, etoposide 200 mg/m2 twice daily ondays -8 to -5 and cyclophosphamide 50 mg/kg on days -3and -2) followed by peripheral blood stem celltransplantation (PBSCT). One patient developedcyclophosphamide-induced severe ataxia during MCVAC,and the second dose of the drug (on day -2) was omitted.Two other patients were diagnosed with pulmonary fibrosisleading to severe restrictive pulmonary impairment at61 and 69 months post-transplant, respectively; one ofthese two patients had undergone whole-lung irradiationbefore transplantation. The remaining two patients werediagnosed with MDS/AML after 20 and 94 months fromPBSCT, respectively; both had previously received salvagechemotherapy and had undergone radiation treatment.Kato J, et al. Safety and efficacy of high-dose ranimustine, cytarabine, etoposideand CY (MCVAC) regimen followed by autologous peripheral blood stem celltransplantation for high-risk diffuse large B-cell lymphoma. Bone MarrowTransplantation 46: 923-928, No. 7, Jul 2011. Available from: URL: http://dx.doi.org/10.1038/bmt.2010.243 - Japan 803059753
» Editorial comment: A search of AdisBase, Medline,Embase and the WHO ADR database did not reveal anyprevious case reports of pulmonary fibrosis associated withranimustine.
1
Reactions 10 Sep 2011 No. 13680114-9954/10/1368-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
